ArticleJournal of pharmaceutical health care and sciences2018

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).

Hisanori Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.